We’re a talented group of scientists and entrepreneurs with a groundbreaking ability to 'see' and characterize new functional allosteric binding sites on proteins for drug development.

 

Our proprietary hydrogen-deuterium exchange LC-MS/MS FastHDX technology can take soluble proteins of interest and map out remote (allosteric) binding sites capable of modulating the active site (orthosteric) and rapidly deliver early allosteric hits against molecular targets with high target selectivity.